Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5279461 | 0.86 | ALOX15 (0.42) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2926028 | 0.77 | HDAC3 (0.41) | MAPTHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL3712470 | 0.75 | TSHR (0.40) | KDM4EMAPTNPC1MEN1KMT2A | |
| SCHEMBL74038 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL5009250 | 0.73 | SPHK2 (0.37) | KDM4EHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5383390 | 0.71 | PPARG (0.61) | — | |
| SCHEMBL3524878 | 0.71 | SLC6A2 (0.32) | — | |
| SCHEMBL5204619 | 0.71 | L3MBTL1 (0.49) | KDM4EMAPTNPC1MEN1KMT2A | |
| SCHEMBL7593855 | 0.70 | MAPT (0.40) | MAPTMEN1KMT2A | |
| SCHEMBL230546 | 0.69 | CTRB1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| EP-1611105-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094386-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | KDM4E 3055/4885MAPT 3017/4885HTT 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.